Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 75

Similar articles for PubMed (Select 20554932)

1.

Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates.

Bello NT, Kemm MH, Ofeldt EM, Moran TH.

Am J Physiol Regul Integr Comp Physiol. 2010 Sep;299(3):R945-52. doi: 10.1152/ajpregu.00275.2010. Epub 2010 Jun 16.

2.

Chronic oxytocin administration inhibits food intake, increases energy expenditure, and produces weight loss in fructose-fed obese rhesus monkeys.

Blevins JE, Graham JL, Morton GJ, Bales KL, Schwartz MW, Baskin DG, Havel PJ.

Am J Physiol Regul Integr Comp Physiol. 2015 Mar 1;308(5):R431-8. doi: 10.1152/ajpregu.00441.2014. Epub 2014 Dec 24.

PMID:
25540103
3.

Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms.

Kanoski SE, Ong ZY, Fortin SM, Schlessinger ES, Grill HJ.

Diabetes Obes Metab. 2015 Mar;17(3):285-93. doi: 10.1111/dom.12423. Epub 2015 Jan 8.

PMID:
25475828
4.

The role of the area postrema in the anorectic effects of amylin and salmon calcitonin: behavioral and neuronal phenotyping.

Braegger FE, Asarian L, Dahl K, Lutz TA, Boyle CN.

Eur J Neurosci. 2014 Oct;40(7):3055-66. doi: 10.1111/ejn.12672. Epub 2014 Jul 21.

PMID:
25040689
5.

Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption.

Wright FL, Rodgers RJ.

Psychopharmacology (Berl). 2014 Sep;231(18):3729-44. doi: 10.1007/s00213-014-3507-4. Epub 2014 Feb 28.

PMID:
24682505
6.

Separation of emetic and anorexic responses of exendin-4, a GLP-1 receptor agonist in Suncus murinus (house musk shrew).

Chan SW, Lin G, Yew DT, Yeung CK, Rudd JA.

Neuropharmacology. 2013 Jul;70:141-7. doi: 10.1016/j.neuropharm.2013.01.013. Epub 2013 Jan 25.

PMID:
23357334
7.

Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose.

Burmeister MA, Ayala J, Drucker DJ, Ayala JE.

Am J Physiol Endocrinol Metab. 2013 Apr 1;304(7):E677-85. doi: 10.1152/ajpendo.00446.2012. Epub 2013 Jan 22.

8.

Vagal afferents mediate early satiation and prevent flavour avoidance learning in response to intraperitoneally infused exendin-4.

Labouesse MA, Stadlbauer U, Weber E, Arnold M, Langhans W, Pacheco-López G.

J Neuroendocrinol. 2012 Dec;24(12):1505-16. doi: 10.1111/j.1365-2826.2012.02364.x.

PMID:
22827554
9.

Additive feeding inhibitory and aversive effects of naltrexone and exendin-4 combinations.

Liang NC, Bello NT, Moran TH.

Int J Obes (Lond). 2013 Feb;37(2):272-8. doi: 10.1038/ijo.2012.16. Epub 2012 Feb 7.

10.

Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner.

Zhao S, Kanoski SE, Yan J, Grill HJ, Hayes MR.

Int J Obes (Lond). 2012 Dec;36(12):1522-8. doi: 10.1038/ijo.2011.265. Epub 2012 Jan 17.

12.

Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.

Hayes MR, Kanoski SE, Alhadeff AL, Grill HJ.

Obesity (Silver Spring). 2011 Jul;19(7):1342-9. doi: 10.1038/oby.2011.50. Epub 2011 Mar 17.

PMID:
21415845
13.

Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats.

Reidelberger RD, Haver AC, Apenteng BA, Anders KL, Steenson SM.

Obesity (Silver Spring). 2011 Jan;19(1):121-7. doi: 10.1038/oby.2010.136. Epub 2010 Jun 17.

PMID:
20559304
14.

GLP-1 antagonism with exendin (9-39) fails to increase spontaneous meal size in rats.

Rüttimann EB, Arnold M, Geary N, Langhans W.

Physiol Behav. 2010 Jun 16;100(4):291-6. doi: 10.1016/j.physbeh.2010.02.022. Epub 2010 Mar 3.

PMID:
20206193
15.

Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight.

Mack CM, Soares CJ, Wilson JK, Athanacio JR, Turek VF, Trevaskis JL, Roth JD, Smith PA, Gedulin B, Jodka CM, Roland BL, Adams SH, Lwin A, Herich J, Laugero KD, Vu C, Pittner R, Paterniti JR Jr, Hanley M, Ghosh S, Parkes DG.

Int J Obes (Lond). 2010 Feb;34(2):385-95. doi: 10.1038/ijo.2009.238. Epub 2009 Nov 24.

PMID:
19935749
16.

Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.

Arakawa M, Ebato C, Mita T, Hirose T, Kawamori R, Fujitani Y, Watada H.

Biochem Biophys Res Commun. 2009 Dec 18;390(3):809-14. doi: 10.1016/j.bbrc.2009.10.054. Epub 2009 Oct 21.

PMID:
19836346
17.

Sibutramine & naloxone: infra-additive interaction in the regulation of appetite?

Tallett AJ, Blundell JE, Rodgers RJ.

Behav Brain Res. 2010 Feb 11;207(1):174-81. doi: 10.1016/j.bbr.2009.10.004. Epub 2009 Oct 8.

PMID:
19818809
18.

The effects of GLP-1 infusion in the hepatic portal region on food intake.

Kim DH, D'Alessio DA, Woods SC, Seeley RJ.

Regul Pept. 2009 Jun 5;155(1-3):110-4. doi: 10.1016/j.regpep.2009.03.002. Epub 2009 Mar 14.

20.

Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.

Roth JD, Trevaskis JL, Wilson J, Lei C, Athanacio J, Mack C, Kesty NC, Coffey T, Weyer C, Parkes DG.

Int J Obes (Lond). 2008 Aug;32(8):1201-10. doi: 10.1038/ijo.2008.91. Epub 2008 Jun 17.

PMID:
18560368
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk